Uncategorized

EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race

EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race

Published

on

EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version